Non-Small Cell Lung Cancer Coverage from Every Angle

Recent News

Predicting Lung Cancer Response to Immunotherapy With Multimodal Genomic Features
Pembrolizumab Plus NK-Cell Therapy for Advanced Lung Cancer
Novel Assay Is Focus of Drug Screening Research in Resistant Lung Cancer
Bispecific Antibody Granted FDA Breakthrough Therapy Designation for Exon 20–Mutated NSCLC
Can Influenza Vaccines Trigger Immune Response in Patients With Lung Cancer?
FDA Accepts Biologics License Application for Proposed Biosimilar to Bevacizumab
Physical Activity and Quality of Life After Radiation Therapy for Lung Cancer
Brigatinib Granted FDA Priority Review for ALK-Positive Metastatic NSCLC
Atezolizumab Receives FDA Priority Review in NSCLC
ASCO-SITC 2020: HLA Expression in Primary Lung Tumors and Brain Metastases
MET Inhibitor Capmatinib Granted FDA Priority Review in Advanced Lung Cancer
ASCO–SITC 2020: Interim Trial Results With Pepinemab/Avelumab in Advanced NSCLC
ASCO-SITC 2020: Radiation Recall Pneumonitis and Nivolumab for Lung Cancer
Priority Review of Selpercatinib in RET-Driven Lung Cancer Granted by FDA
STS 2020: Intraoperative Molecular Imaging During Surgery for NSCLC
Priority Review Granted by FDA to Immunotherapy Combination in Lung Cancer
PET Imaging of Mitochondrial Activity in Lung Tumor Cells
FLAURA Trial: Overall Survival With Osimertinib in EGFR-Mutated Lung Cancer
Can Skin Reactions Portend Clinical Benefit in Patients With NSCLC?
ESMO I-O 2019: Overall Survival With Nivolumab/Ipilimumab in Lung Cancer
RSNA 2019: Deep Learning Tool and Cardiovascular Health on Lung Cancer Screenings
Atezolizumab/Chemotherapy Approved by FDA in First-Line Treatment of Metastatic Lung Cancer
Case Studies: Possible Link Between Nivolumab for Lung Cancer and Pericardial Effusion
Final Overall Survival With Atezolizumab/Chemotherapy in Advanced Lung Cancer
Early Study Findings With Novel KRAS Inhibitor in Advanced Lung Cancers
SITC 2019: Atezolizumab Monotherapy Versus Chemotherapy in PD-L1–Selected Lung Cancer
ASCEND-7: Ceritinib for Brain Metastases From ALK-Positive Lung Cancer
3-Year Survival Update of KEYNOTE-024: Comparison of Pembrolizumab and Chemotherapy
Prognostic Indicators Among Patients With EGFR-Positive NSCLC
Investigational Drug Under Study in KRAS G12C–Mutant Lung Cancer
Mutations Linked to Poorer Outcomes in Lung Cancer Identified in MYSTIC Trial
ESMO 2019: Tissue Tumor Mutational Burden and Survival With Pembrolizumab in Lung Cancer
ASCO Breakthrough 2019: Lung Cancer Diagnosis Tool Takes CAD to New Dimensions
ESMO 2019: Liquid Biopsy May Guide Therapy for Some Patients With Lung Cancer
First-in-Human Trial of Anti-AXL Antibody-Drug Conjugate in Advanced Lung Cancer
ESMO 2019: First-Line Osimertinib in Patients With EGFR-Mutated Advanced NSCLC

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.